VEGFA and Thrombocytopenia: ~83% of patients treated with zFOLFIRI in the original VELOUR study experienced a grade 3 or 4 adverse event, including VEGF-specific events [i.e., arterial (1.8%) or venous (7.9%) thromboembolism, hemorrhage (2.9%), or hypertension (19%)] as well as chemotherapy related events, such as diarrhea (19%), thrombocytopenia (3.3%) and febrile neutropenia (5.7%) (9).